Analysts expect that Heat Biologics Inc (NASDAQ:HTBX) will report sales of $1.50 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Heat Biologics’ earnings. The highest sales estimate is $1.80 million and the lowest is $1.20 million. The business is expected to issue its next earnings report on Thursday, February 21st.
According to Zacks, analysts expect that Heat Biologics will report full-year sales of $5.22 million for the current year, with estimates ranging from $4.90 million to $5.54 million. For the next financial year, analysts forecast that the company will post sales of $4.95 million, with estimates ranging from $4.80 million to $5.10 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Heat Biologics.
Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Thursday, November 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $1.84 million during the quarter, compared to analysts’ expectations of $1.50 million. Heat Biologics had a negative net margin of 331.02% and a negative return on equity of 94.53%.
HTBX has been the subject of several recent analyst reports. HC Wainwright set a $6.00 price objective on shares of Heat Biologics and gave the company a “buy” rating in a report on Friday, November 16th. ValuEngine upgraded shares of Heat Biologics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.
Heat Biologics stock opened at $1.25 on Friday. Heat Biologics has a 12-month low of $0.95 and a 12-month high of $4.50.
A number of large investors have recently modified their holdings of HTBX. Northern Trust Corp bought a new stake in Heat Biologics during the second quarter worth approximately $111,000. Vanguard Group Inc boosted its holdings in Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 136,256 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 136,256 shares in the last quarter. Hedge funds and other institutional investors own 4.46% of the company’s stock.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.